Jump to content
ADVANCED CASE SEARCH
An affiliate of the U.S. Chamber of Commerce
Results are sorted by the date of most recent activity.
U.S. Supreme Court holds that judges, rather than juries, must decide whether federal prescription-drug regulations preempt state failure-to-warn claims. The Chamber urged the Court to take this...
En banc Ninth Circuit unanimously holds that San Francisco’s required health warnings for sugary drinks violate beverage makers’ constitutional free speech rights
Supreme Court declines to review circuit split on materiality under False Claims Act
U.S. Chamber files coalition amicus brief at merits stage, arguing Supreme Court should reverse Third Circuit’s mistaken approach to Wyeth v. Levine’s “clear evidence” standard
First Circuit affirms judgment that federal law preempts plaintiffs’ state-law claims against pharmaceutical companies’ refusal to alter size of eye-drop bottle
Seventh Circuit reverses $3 million verdict against GlaxoSmithKline, concluding plaintiffs’ negligent failure to warn claims were preempted by federal law
Supreme Court grants cert. petition regarding scope of conflict preemption after Wyeth v. Levine
Fourth Circuit upholds district court’s “gate keeping” decision under the Daubert standard, excluding unreliable and questionable expert testimony from product liability cases
Supreme Court denies cert. petition asking whether plaintiffs have standing to pursue class action alleging that prescription eye drops dispensed too much medication
West Virginia Supreme Court of Appeals rejects “innovator liability” theory for manufacturers of FDA approved medication